Analyst Research

Report Title Price
Provider : Thomson Reuters Stock Report
Provider : Stock Traders Daily
Provider : New Constructs, LLC
Provider : ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Eli Lilly And Co Raises Low End Of Prior FY 2013 EPS Guidance To A Range In Line with Analysts' Estimates; Reaffirms FY 2013 Revenue Guidance

Wednesday, 23 Oct 2013 06:30am EDT 

Eli Lilly And Co announced it has narrowed its fiscal 2013 earnings per share (EPS) guidance and expects EPS to be in the range of $4.33 to $4.38 on a reported basis, or $4.10 to $4.15 on a non-GAAP basis. The Company still anticipates fiscal 2013 revenue of between $22.6 billion and $23.4 billion. The Company expects overall revenue growth in 2013, driven by a portfolio of products including Humalog, Humulin, Cialis, Strattera, Forteo, Alimta, Cymbalta outside the U.S., Effient, Trajenta and Axiron, as well as animal health products. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenues of $22.9 billion and EPS of $4.14 for fiscal 2013.